Slingshot members are tracking this event:
Regeneron Pharmaceuticals (REGN) trial on DUPIXENT (dupilumab) in food allergy set to begin in second half of 2017
Slingshot Insights Explained
Oct 16, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Dupixent, Dupilumab, Food Allergy